Royalty Pharma
- Market cap
- 25.27B
- P/E (TTM)i
- 30.52
- P/Bi
- 3.70
- EPSi
- 1.78
- Div yieldi
- 1.60%
- 52W posi
- 74%
Anonymous reader poll. Unscientific, not investment advice.
About Royalty Pharma
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
- Founded
- 2020
- CEO
- Mr. Pablo Legorreta
- Employees
- 100
- Headquarters
- New York, New York, United States of America
- Fiscal year end
- 12-31
- Website
- royaltypharma.com
Company profile
- Exchange
- US
- Symbol
- RPRX
- Market-cap rank
- #759
- Listing date
- 2020-06-16
- Market cap
- 25.27B
- Float cap
- 23.59B
- Shares out
- 445.28M
- Float shares
- 415.52M
Sectors & themes
Quote time 2026-10-08 06:30:58 · For reference only, not investment advice and not tailored to your situation.